Spots Global Cancer Trial Database for flutamide
Every month we try and update this database with for flutamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence | NCT00003645 | Prostate Cancer | Flutamide Leuprolide Acet... | - | M.D. Anderson Cancer Center | |
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women | NCT01889199 | Polycystic Ovar... | Flutamide Placebo | 18 Years - 35 Years | University of California, Los Angeles | |
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | NCT02742675 | Prostate Cancer | Bicalutamide goserelin aceta... flutamide leuprolide acet... triptorelin Definitive Trea... | 18 Years - 80 Years | Fudan University | |
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | NCT00767286 | Prostate Cancer | flutamide goserelin aceta... low-LET cobalt-... low-LET photon ... | 50 Years - | National Cancer Institute (NCI) | |
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer | NCT00028769 | Prostate Cancer | bicalutamide estramustine etoposide flutamide goserelin leuprolide nilutamide paclitaxel | 18 Years - | SWOG Cancer Research Network | |
Hormone Therapy in Treating Patients With Advanced Prostate Cancer | NCT00003026 | Prostate Cancer | bicalutamide flutamide triptorelin radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer | NCT00054106 | Prostate Cancer | buserelin custirsen sodiu... flutamide conventional su... neoadjuvant the... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone | NCT01428193 | Polycystic Ovar... Hyperandrogenis... | Flutamide Progesterone estrace | 13 Years - 17 Years | University of Virginia | |
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | NCT00388804 | Prostate Cancer | Radiation Thera... Bicalutamide Leuprolide Goserelin Flutamide Questionnaire | - | M.D. Anderson Cancer Center | |
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | NCT00170157 | Prostate Adenoc... Prostate Carcin... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Bicalutamide Flutamide Goserelin Aceta... Ipilimumab Leuprolide Acet... Pharmacological... | 18 Years - | Mayo Clinic | |
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | NCT00026377 | Prostate Cancer | bicalutamide flutamide goserelin aceta... leuprolide acet... SU5416 radiation thera... | - | University of Chicago | |
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | NCT00651326 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... neoadjuvant the... quality-of-life... radiation thera... Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. | NCT02346578 | Castration-resi... | Enzalutamide Flutamide | 20 Years - | Osaka City University | |
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | NCT01786265 | Prostate Adenoc... Recurrent Prost... | Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | NCT00002889 | Prostate Cancer | flutamide goserelin leuprolide acet... low-LET photon ... | 30 Years - | Alliance for Clinical Trials in Oncology | |
Radiation Therapy for Rising Prostate Specific Antigen (PSA) Post-prostatectomy | NCT00850941 | Prostate Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | NCT00699907 | Ovarian Cancer | flutamide | 18 Years - 83 Years | University of Arizona | |
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | NCT00767286 | Prostate Cancer | flutamide goserelin aceta... low-LET cobalt-... low-LET photon ... | 50 Years - | National Cancer Institute (NCI) | |
Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion | NCT04597099 | PCOS Polycystic Ovar... | Micronized prog... Placebo Flutamide Estradiol patch | 18 Years - 30 Years | University of Virginia | |
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | NCT00528866 | Prostate Cancer | bicalutamide docetaxel flutamide LHRH agonist 3-dimensional c... radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer | NCT00003653 | Prostate Cancer | bicalutamide buserelin cyproterone ace... flutamide goserelin leuprolide acet... nilutamide | 16 Years - 120 Years | Canadian Cancer Trials Group | |
Hormone Therapy in Treating Patients With Prostate Cancer | NCT00003323 | Prostate Cancer Sexual Dysfunct... | finasteride flutamide quality-of-life... | - | Alliance for Clinical Trials in Oncology | |
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer | NCT00004054 | Prostate Cancer | bicalutamide estramustine ph... etoposide flutamide paclitaxel Luteinizing hor... Radiation thera... warfarin | 18 Years - | Radiation Therapy Oncology Group | |
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression | NCT03507608 | Prostate Cancer | Flutamide Placebo | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer | NCT00512668 | Adenocarcinoma ... Recurrent Prost... | leuprolide acet... goserelin aceta... bicalutamide nilutamide flutamide temsirolimus laboratory biom... | - | National Cancer Institute (NCI) | |
Hormone Therapy in Treating Patients With Advanced Prostate Cancer | NCT00003026 | Prostate Cancer | bicalutamide flutamide triptorelin radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer | NCT02918968 | Prostate Cancer | Enzalutamide Flutamide Androgen depriv... | 20 Years - | Astellas Pharma Inc | |
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer | NCT00054106 | Prostate Cancer | buserelin custirsen sodiu... flutamide conventional su... neoadjuvant the... | 18 Years - 120 Years | Canadian Cancer Trials Group | |
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c | NCT00817739 | Prostatic Neopl... | Leuprorelin Flutamide | 18 Years - | Takeda | |
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer | NCT00936390 | Prostate Cancer | bicalutamide flutamide LHRH agonist (a... Dose-Escalated ... | 18 Years - | Radiation Therapy Oncology Group | |
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer | NCT00003124 | Prostate Cancer | flutamide leuprolide acet... radiation thera... | - | National Cancer Institute (NCI) | |
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | NCT00002597 | Prostate Cancer | flutamide Zoladex Lupron radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | NCT00003517 | Adenocarcinoma ... Stage III Prost... Stage IV Prosta... Recurrent Prost... | antineoplaston ... antineoplaston ... bicalutamide flutamide leuprolide acet... alternative pro... antiandrogen th... biological ther... biologically ba... cancer preventi... complementary a... differentiation... endocrine thera... hormone therapy | 18 Years - | National Cancer Institute (NCI) | |
Effect of High Testosterone on Sleep-associated Slowing of Follicular Luteinizing Hormone (LH) Frequency in Polycystic Ovary Syndrome | NCT00930228 | Polycystic Ovar... | Flutamide Placebo | 18 Years - 35 Years | University of Virginia | |
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer | NCT00002881 | Prostate Cancer | flutamide goserelin aceta... leuprolide acet... suramin therapeutic hyd... orchiectomy | 18 Years - | National Cancer Institute (NCI) | |
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma | NCT01011751 | Adenocarcinoma,... | Cyproterone ace... Medroxyprogeste... Venlafaxine Leuprorelin Flutamide Placebo | 18 Years - | Takeda | |
Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome | NCT00729560 | Polycystic Ovar... | Flutamide Placebo | 18 Years - 40 Years | Virginia Commonwealth University | |
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | NCT03678025 | Castration Leve... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Bicalutamide Degarelix Docetaxel Flutamide Goserelin Aceta... Histrelin Aceta... Leuprolide Acet... Nilutamide Orchiectomy Prednisone Quality-of-Life... Radiation Thera... Radical Prostat... Triptorelin | 18 Years - | SWOG Cancer Research Network | |
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer | NCT00002633 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... nilutamide orchiectomy radiation thera... | - 79 Years | Canadian Cancer Trials Group | |
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | NCT00002889 | Prostate Cancer | flutamide goserelin leuprolide acet... low-LET photon ... | 30 Years - | Alliance for Clinical Trials in Oncology | |
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | NCT00030654 | Prostate Cancer | bicalutamide docetaxel doxorubicin hyd... estramustine ph... flutamide ketoconazole paclitaxel releasing hormo... vinblastine sul... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer | NCT00023829 | Prostate Cancer | bicalutamide flutamide releasing hormo... adjuvant therap... radiation thera... | 0 Years - 120 Years | Radiation Therapy Oncology Group | |
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c | NCT00817739 | Prostatic Neopl... | Leuprorelin Flutamide | 18 Years - | Takeda | |
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer | NCT00003734 | Prostate Cancer | flutamide triptorelin radiation thera... | 18 Years - 120 Years | National Cancer Institute (NCI) | |
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer | NCT00651326 | Prostate Cancer | bicalutamide buserelin flutamide goserelin leuprolide acet... neoadjuvant the... quality-of-life... radiation thera... Docetaxel | 18 Years - | Canadian Cancer Trials Group | |
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | NCT00388804 | Prostate Cancer | Radiation Thera... Bicalutamide Leuprolide Goserelin Flutamide Questionnaire | - | M.D. Anderson Cancer Center | |
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer | NCT00002881 | Prostate Cancer | flutamide goserelin aceta... leuprolide acet... suramin therapeutic hyd... orchiectomy | 18 Years - | National Cancer Institute (NCI) | |
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer | NCT00030654 | Prostate Cancer | bicalutamide docetaxel doxorubicin hyd... estramustine ph... flutamide ketoconazole paclitaxel releasing hormo... vinblastine sul... | 18 Years - 120 Years | Radiation Therapy Oncology Group | |
Metabolic Syndrome in PCOS: Precursors and Interventions | NCT00442689 | Polycystic Ovar... Metabolic Syndr... | flutamide ethinyl estradi... placebo | 18 Years - 35 Years | Northwestern University | |
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer | NCT00223665 | Prostate Cancer | Flutamide Leuprolide Acet... | 21 Years - | University of Washington | |
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | NCT03678025 | Castration Leve... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Bicalutamide Degarelix Docetaxel Flutamide Goserelin Aceta... Histrelin Aceta... Leuprolide Acet... Nilutamide Orchiectomy Prednisone Quality-of-Life... Radiation Thera... Radical Prostat... Triptorelin | 18 Years - | SWOG Cancer Research Network | |
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer | NCT00023829 | Prostate Cancer | bicalutamide flutamide releasing hormo... adjuvant therap... radiation thera... | 0 Years - 120 Years | Radiation Therapy Oncology Group | |
Metabolic Syndrome in PCOS: Precursors and Interventions | NCT00442689 | Polycystic Ovar... Metabolic Syndr... | flutamide ethinyl estradi... placebo | 18 Years - 35 Years | Northwestern University |